Hikma Pharmaceuticals Management
Management criteria checks 2/4
Hikma Pharmaceuticals' CEO is Riad Mishlawi, appointed in Sep 2023, has a tenure of 1.25 years. total yearly compensation is $1.55M, comprised of 21.5% salary and 78.5% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth £2.60M. The average tenure of the management team and the board of directors is 1.3 years and 5.5 years respectively.
Key information
Riad Mishlawi
Chief executive officer
US$1.6m
Total compensation
| CEO salary percentage | 21.5% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.06% |
| Management average tenure | 1.3yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark
Nov 11
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Oct 24Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$285m |
| Mar 31 2024 | n/a | n/a | US$238m |
| Dec 31 2023 | US$2m | US$333k | US$190m |
Compensation vs Market: Riad's total compensation ($USD1.55M) is below average for companies of similar size in the UK market ($USD3.47M).
Compensation vs Earnings: Insufficient data to compare Riad's compensation with company performance.
CEO
Riad Mishlawi (60 yo)
1.3yrs
Tenure
US$1,552,833
Compensation
Mr. Riad Ali Mishlawi serves as Chief Executive Officer of Hikma Pharmaceuticals PLC since September 01, 2023 and serves as its Director since September 01, 2023. He had been the President of Injectables s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 17.4yrs | US$3.57m | 0.38% £ 16.6m | |
| CEO & Director | 1.3yrs | US$1.55m | 0.060% £ 2.6m | |
| Executive Vice Chairman & President of MENA | 19.3yrs | US$2.84m | 0.63% £ 27.2m | |
| Chief Financial Officer | 13.9yrs | no data | 0.20% £ 8.8m | |
| Chief Information Officer | no data | no data | no data | |
| Associate Director of Investor Relations | no data | no data | no data | |
| General Counsel | no data | no data | no data | |
| Executive Vice President of Corporate Development and M&A | 10.8yrs | no data | 0.26% £ 11.2m | |
| Chief People Officer | 1.3yrs | no data | no data | |
| Executive Vice President of Strategic Planning & Global Affairs | 6.9yrs | no data | no data | |
| President of Injectables Business | 1.3yrs | no data | no data | |
| Senior Vice President of Corporate Quality Compliance/Health & Safety | less than a year | no data | no data |
1.3yrs
Average Tenure
60yo
Average Age
Experienced Management: HIK's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 17.4yrs | US$3.57m | 0.38% £ 16.6m | |
| CEO & Director | 1.3yrs | US$1.55m | 0.060% £ 2.6m | |
| Executive Vice Chairman & President of MENA | 19.3yrs | US$2.84m | 0.63% £ 27.2m | |
| Senior Independent Non-Executive Director | 2.1yrs | US$149.27k | no data | |
| Independent Non-Executive Director | 8.2yrs | US$176.38k | 0.0032% £ 138.6k | |
| Independent Non-Executive Director | 8.8yrs | US$159.69k | 0.0016% £ 68.4k | |
| Non-Executive Director | 19.2yrs | US$116.72k | 0.52% £ 22.7m | |
| Independent Non-Executive Director | 4.6yrs | US$149.85k | 0.0020% £ 87.9k | |
| Independent Non-Executive Director | 2.1yrs | US$127.05k | 0.00045% £ 19.5k | |
| Independent Non-Executive Director | 5.5yrs | US$134.68k | 0.00050% £ 21.7k | |
| Chairman of West-ward Pharmaceuticals | no data | no data | no data | |
| Independent Non-Executive Director | 2.2yrs | US$124.98k | no data |
5.5yrs
Average Tenure
66yo
Average Age
Experienced Board: HIK's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hikma Pharmaceuticals PLC is covered by 38 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| Simon Mather | Barclays |
| Emily Field | Barclays |